Rezolute, Inc. (RZLT)
4.48
-0.21
(-4.48%)
USD |
NASDAQ |
Sep 01, 16:00
4.48
0.00 (0.00%)
After-Hours: 20:00
Rezolute Research and Development Expense (Annual) : 61.53M for June 30, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2025 | 61.53M |
| June 30, 2024 | 55.74M |
| June 30, 2023 | 43.81M |
| June 30, 2022 | 32.49M |
| June 30, 2021 | 14.99M |
| June 30, 2020 | 14.45M |
| June 30, 2019 | 19.08M |
| June 30, 2018 | 17.28M |
| Date | Value |
|---|---|
| June 30, 2017 | 12.09M |
| June 30, 2016 | 9.448M |
| June 30, 2015 | 4.701M |
| June 30, 2014 | 0.0343M |
| June 30, 2013 | 0.0035M |
| June 30, 2012 | 0.0048M |
| June 30, 2011 | 0.0245M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| SELLAS Life Sciences Group, Inc. | 16.02M |
| AbbVie, Inc. | 8.249B |
| Marker Therapeutics, Inc. | 11.80M |
| Avalo Therapeutics, Inc. | 50.08M |
| Krystal Biotech, Inc. | 52.32M |